CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

Cytek Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$5.25+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $679.67M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Cytek Biosciences reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Cytek Biosciences's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Cytek Biosciences's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CTKB.

Revenue growth5.4% · median 2.0%

Gross margin53.2% · median 47.5%

Operating margin-21.6% · median -83.5%

Net margin-32.2% · median -80.2%

Company	Revenue	Growth
TXG	$616.91M	-4.3%
CTKB	$206.71M	+5.4%
PACB	$159.27M	+2.0%
QTRX	$153.41M	+22.0%
HBIO	$87.81M	-1.1%
BNGO	$30.18M	+10.0%

Company

Next earnings (est.): Nov 4, 2026, during market hours
Exchange: Nasdaq
Industry: Laboratory Analytical Instruments
Fiscal year ends: December 31
Employees: 702
Held by institutions: 62.7%
Auditor: Deloitte & Touche LLP
SEC CIK: 1831915

Advertisement
300 × 250